Comparing Cyclacel Pharmaceuticals (BGMS) and The Competition

Cyclacel Pharmaceuticals (NASDAQ:BGMS) is one of 453 public companies in the “Pharmaceutical Preparations” industry, but how does it weigh in compared to its peers? We will compare Cyclacel Pharmaceuticals to related businesses based on the strength of its profitability, institutional ownership, analyst recommendations, dividends, valuation, risk and earnings.

Analyst Recommendations

This is a breakdown of current ratings and price targets for Cyclacel Pharmaceuticals and its peers, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cyclacel Pharmaceuticals	1	0	0	0	1.00
Cyclacel Pharmaceuticals Competitors	4823	9974	16015	372	2.38

As a group, “Pharmaceutical Preparations” companies have a potential upside of 118.85%. Given Cyclacel Pharmaceuticals’ peers stronger consensus rating and higher possible upside, analysts plainly believe Cyclacel Pharmaceuticals has less favorable growth aspects than its peers.

Earnings & Valuation

This table compares Cyclacel Pharmaceuticals and its peers top-line revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Cyclacel Pharmaceuticals	$81,000.00	-$11.21 million	-0.02
Cyclacel Pharmaceuticals Competitors	$437.46 million	-$68.67 million	-10.41

Cyclacel Pharmaceuticals’ peers have higher revenue, but lower earnings than Cyclacel Pharmaceuticals. Cyclacel Pharmaceuticals is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.

Profitability

This table compares Cyclacel Pharmaceuticals and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Cyclacel Pharmaceuticals	N/A	-187.37%	-106.68%
Cyclacel Pharmaceuticals Competitors	-2,625.49%	-359.57%	-43.35%

Risk & Volatility

Cyclacel Pharmaceuticals has a beta of 0.04, suggesting that its share price is 96% less volatile than the S&P 500. Comparatively, Cyclacel Pharmaceuticals’ peers have a beta of 10.20, suggesting that their average share price is 920% more volatile than the S&P 500.

Insider & Institutional Ownership

23.6% of Cyclacel Pharmaceuticals shares are held by institutional investors. Comparatively, 39.4% of shares of all “Pharmaceutical Preparations” companies are held by institutional investors. 51.2% of Cyclacel Pharmaceuticals shares are held by company insiders. Comparatively, 14.1% of shares of all “Pharmaceutical Preparations” companies are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

Cyclacel Pharmaceuticals peers beat Cyclacel Pharmaceuticals on 8 of the 13 factors compared.

Cyclacel Pharmaceuticals Company Profile

Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company’s development programs include fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and CYC140, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced leukemias and solid tumors. Its development programs also comprise Sapacitabine, a novel nucleoside analog that is orally available prodrug of CNDAC, which is in Phase 1/2 clinical trials to treat acute myeloid leukemia and myelodysplastic syndrome; and seliciclib, a CDK inhibitor that is in Phase 2 investigator-sponsored trials (IST) for Cushing’s disease, as well as in Phase 1/2 IST for the treatment for advanced rheumatoid arthritis. The company has a clinical collaboration agreement with the University of Texas MD Anderson Cancer Center to clinically evaluate the safety and efficacy of three cyclacel medicines in patients with hematological malignancies, including chronic lymphocytic leukemias, acute myeloid leukemias, myelodysplastic syndromes, and other advanced leukemias. Cyclacel Pharmaceuticals, Inc. is headquartered in Berkeley Heights, New Jersey.